It's the moment of truth for Akeso's ivonescimab, and to many, a high-stakes test for China's boomin...
ASCO: Akeso’s ivonescimab bests PD-1 inhibitor in lung cancer chemo combos, slashing death risk by 34%
It's the moment of truth for Akeso's ivonescimab, and to many, a high-stakes test for China's booming biotech industry. And the first-in-class PD-1xVEGF...
Author: Fierce Pharma
Read Original Article